The COL9A2 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal cell population in which the COL9A2 gene has been disrupted in the Raji human B lymphocyte line. This product is provided as a heterogeneous knockout pool, enabling loss-of-function studies without the need for single-cell cloning. The editing strategy leverages CRISPR/Cas9-mediated gene disruption to ablate COL9A2 expression, generating a versatile tool for functional genomics and control experiments in B cell contexts.
The Raji cell line is an EBV-positive Burkitt lymphoma-derived B lymphocyte model characterized by surface IgM-negative status and robust proliferative capacity. Widely employed in lymphomagenesis research and humoral immunity studies, Raji cells offer a well-defined genetic background for investigating B cell biology. Their transformed phenotype and ease of culture make them suitable for high-throughput screening and mechanistic assays, including those involving ectopic gene expression or signaling pathway interrogation.
COL9A2 encodes the ??2 chain of type IX collagen, a crucial component of cartilage extracellular matrix that covalently cross-links to type II collagen fibrils, stabilizing the matrix network. This protein is regulated by the SOX9 transcription factor and TGF-??/BMP signaling, while also responding to mechanical stress. It interacts with collagen type II, collagen type XI, matrilin-1, matrilin-3, COMP, and decorin, and promotes downstream integrin-mediated signaling via FAK. In physiological settings, COL9A2 is essential for cartilage development and integrity; however, it is not typically expressed in lymphoid cells. In the Raji B cell background, the knockout eliminates any potential background expression, providing a clean slate for studying the consequences of ectopic COL9A2 introduction or for serving as a negative control.
Given the Raji cell line??s lymphoid origin, the COL9A2 knockout is particularly valuable as a non-expressing control in experiments that aim to elucidate collagen-related signaling pathways in non-cartilage contexts. It enables researchers to distinguish between B cell-specific phenotypes and those induced by exogenous collagen expression. Moreover, this model can be employed to explore whether aberrant COL9A2 expression influences B cell proliferation, survival, or drug responses, thereby contributing to a deeper understanding of potential cross-talk between collagen matrix signals and lymphomagenesis.
The polyclonal knockout cells are suitable for a broad range of applications, including CRISPR screening normalization, B cell functional genomics, and drug sensitivity profiling. In practice, researchers can validate gene disruption via PCR genotyping and Sanger sequencing, confirm loss of protein expression by Western blotting, and assess basic cellular characteristics using flow cytometry for B cell markers and viability assays. Transcriptomic effects can be evaluated through RNA-seq, allowing for comprehensive pathway analysis. These cells serve as a robust control in assays investigating collagen biology outside the cartilage environment. For further technical details or ordering information, please contact Ascent Research.
